MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $20.13 (53.16% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetActions
5/31/2016WedbushBoost Price TargetOutperform$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Needham & Company LLCReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015GabelliUpgradeSell -> Hold$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Stifel NicolausLower Price TargetBuy$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q3($0.36)($0.34)$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q3($0.05)($0.08)$0.16 million$0.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateHeadline
06/27/16 09:23 AMNext Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Fiscal Standard
06/27/16 09:23 AMEquity Research and Technical Review on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
06/27/16 09:23 AMStock Performance Focus on: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
06/22/16 09:00 AMFrank Palantoni joins Laboratoire M2 as CEO - [GlobeNewswire] - SHERBROOKE, Québec, June 22, 2016-- Laboratoire M2, the company behind THYMOX™, the new standard in environmentally sustainable disinfecting technologies, is proud to announce that Frank Palantoni, a seasoned ...
06/21/16 04:43 PMRecently Issued Stock Ratings For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Fiscal Standard
06/21/16 12:08 PMETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 21, 2016 -
06/20/16 07:29 AMLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : June 20, 2016 -
06/20/16 06:28 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 07:49 AMTrending Analyst Recommended Stock: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - News Oracle
06/13/16 07:55 AMStock's Price Moves: Cerus Corporation (NASDAQ:CERS) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Street Updates
06/12/16 07:47 AMWill Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Surprise Analysts? - Investor Newswire
06/09/16 05:18 PMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Fundamental Star Rating Report - CML News
06/09/16 12:27 PMETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 9, 2016 -
06/08/16 08:50 AMLexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/06/16 04:56 PMLEXICON PHARMACEUTICALS INC. (NASDAQ:LXRX) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:12 AMPremarket Research Report Covering the Biotech Industry -
06/05/16 05:03 PMPerformance Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - HNN
06/03/16 05:28 PMLexicon Pharma (LXRX) Launches New Carcinoid Syndrome Disease Education Website - StreetInsider.com
06/02/16 05:22 PMWedbush Analysts Reduce Earnings Estimates for Lexicon Pharmaceuticals, Inc. (LXRX) - Let Me Know About This - Wedbush Analysts Reduce Earnings Estimates for Lexicon Pharmaceuticals, Inc. (LXRX)Let Me Know About ThisLexicon Pharmaceuticals logo Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Wedbush dropped their FY2016 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, according to Zacks ...Lexicon Pharma (LXRX) Launches New Carcinoid Syndrome Disease Education WebsiteStreetInsider.comall 3 news articles »
06/02/16 03:55 PMLexicon Announces the Launch of AboutCarcinoid.com to Provide Carcinoid Syndrome Disease Education to Patients, Caregivers and Physicians - [at noodls] - Commencement of the Carcinoid Syndrome Impact Survey The Woodlands, Texas, June 2, 2016 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid ...
06/02/16 07:54 AMSummary of Price Movements: Novo Nordisk A/S (NYSE:NVO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Street Updates - Summary of Price Movements: Novo Nordisk A/S (NYSE:NVO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Street UpdatesIn the past trading session, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended trading session higher at $14.54 with +2.32%. The company traded a volume of 961.76 thousand shares as comparison to average volume of 758.6 thousand shares. During ...
06/01/16 07:52 AMNews Sentiment For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Investor Newswire - News Sentiment For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Investor NewswireLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Average broker stands at 2.4 while it was 2.4 three months ago. The quarterly report of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) can be made public close to 2016-08-05. It is estimated by the recent ...and more »
06/01/16 07:52 AMStock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Announces FDA Priority Review of New Drug ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Announces FDA Priority Review of New Drug ...Smarter AnalystLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has granted a ...Wedbush Boosts Lexicon Pharmaceuticals, Inc. (LXRX) Price Target to $30.00The Cerbat GemLexicon Pharma Says FDA Accepts Carcinoid Syndrome Treatment NDA For Priority Review; Shares Rise 3 ...Sonoran Weekly Reviewall 6 news articles »
05/31/16 05:13 PMStock Review and Earnings Check on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - HNN - Stock Review and Earnings Check on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Lexicon Pharmaceuticals, Inc.and more »
05/31/16 09:11 AMLexicon Pharma (LXRX) Announces FDA Priority Review of NDA For Telotristat Etiprate for Treatment of Carcinoid Syndrome - Claim your 2-week free trial to StreetInsider Premium here. Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for ...
05/30/16 09:58 PMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) 1-Year High At $15.79 - Stocks Daily - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) 1-Year High At $15.79Stocks DailyThe technical analysis of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlights the stock is $0.40 points away +3.00% from 50-day MA of $13.28. It is $1.65 or +13.69% away $12.03, the stock's 200-day MA. Yesterday, the stock of Lexicon ...Are Analysts Bearish Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Last Week?Franklin IndependentAfter Last Week What Do Analysts Think Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Share Trading NewsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) One-Year Price Target At $20.10Markets Dailyall 11 news articles »
05/30/16 08:48 AMTarget Check and Stock Performance Recap Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - HNN - Target Check and Stock Performance Recap Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)HNNIn recent session activity, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares have traded +1.63%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
05/26/16 07:37 PMLexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : May 27, 2016 -
05/26/16 08:48 AMStock Rating Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Hints and News - Stock Rating Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 2.4 on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/25/16 10:37 PMLXRX January 2017 Options Begin Trading - Investors in Lexicon Pharmaceuticals, Inc. (Symbol: LXRX) saw new options become available today, for the January 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days ...
05/25/16 10:37 PMLexicon Pharmaceuticals Inc. (LXRX) Jumps 7.48% on May 23 - Lexicon Pharmaceuticals Inc. (LXRX) was among the biggest gainers on the Russell 2000 for Monday May 23 as the stock popped 7.48% to $13.37, representing a gain of $0.93 per share. Some 3.52 million shares traded hands on 6,805 trades, compared with an ...
05/25/16 08:46 AMPrice Movers of Last Trading Day: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) , Align Technology, Inc. (NASDAQ ... - Street Updates - Price Movers of Last Trading Day: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) , Align Technology, Inc. (NASDAQ ...Street UpdatesIn the liquidity ratio analysis; Lexicon Pharmaceuticals, Inc.'s (LXRX) debt to equity ratio was 0.41 while current ratio was 4.00. The company has the institutional ownership of 95.20% while the Beta factor was 1.39. The stock's RSI amounts to 52.40.and more »
05/25/16 08:46 AMLexicon Pharmaceuticals Inc. (LXRX) is Trading Higher on Unusual Volume for May 23 - Equities.com - Lexicon Pharmaceuticals Inc. (LXRX) is Trading Higher on Unusual Volume for May 23Equities.comLexicon Pharmaceuticals Inc. (LXRX) experienced unusually high volume on May. 23, as the stock gained 7.48% to a closing price of $13.37. The stock saw 3.52 million shares trade hands over the course of the day on 6,805 trades. Given that the stock's ...
05/24/16 10:42 PMLexicon Pharmaceuticals Inc. (LXRX) Jumps 7.48% on May 23 - Equities.com - Lexicon Pharmaceuticals Inc. (LXRX) Jumps 7.48% on May 23Equities.comLexicon Pharmaceuticals Inc. (LXRX) was among the biggest gainers on the Russell 2000 for Monday May 23 as the stock popped 7.48% to $13.37, representing a gain of $0.93 per share. Some 3.52 million shares traded hands on 6,805 trades, compared ...
05/24/16 09:13 AMStocks within Analysts Screening: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , Lexicon Pharmaceuticals, Inc ... - Street Updates - Stocks within Analysts Screening: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , Lexicon Pharmaceuticals, Inc ...Street UpdatesLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) after beginning at $12.44, closed at $13.37 by building up +7.48% in recent trading session. Most recent session's volume of 3.53 million shares greater than its average volume of 777.99 thousand shares.and more »
05/24/16 09:13 AMInsider Trading in Focus: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - The Point Review - The Point ReviewInsider Trading in Focus: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)The Point ReviewLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) insiders have most recently took part in a trading activity. On 2/29/2016 Tessmes James F, VP, Finance & Accounting sold 1,626 shares having total worth of $14,748 at the price of $9.07 per share, following ...Stock to Watch: Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX)CWRU ObserverNew Analyst Ratings On Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Risers & FallersLexicon Pharmaceuticals, Inc. (LXRX) Files Form 4 Insider Selling : James F Tessmer Sells 6000 SharesMarket DigestStreet Updates -Wall Street Hints and News -Hot Stocks Pointall 13 news articles »
05/24/16 07:10 AMLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : May 24, 2016 -
05/23/16 05:31 PMTarget Check and Stock Performance Recap Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Hints and News - Target Check and Stock Performance Recap Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Lexicon Pharmaceuticals, Inc.
05/23/16 10:28 AMLatest Price movements of Stocks: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) , Lexicon Pharmaceuticals, Inc ... - Street Updates - Latest Price movements of Stocks: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) , Lexicon Pharmaceuticals, Inc ...Street UpdatesIn the past trading session, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlighted upward shift of +1.22% or +0.15 points to $12.44. The company traded a volume of 850.69 thousand shares over average volume of 723.46 thousand shares. Trailing ...Next Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Share Trading NewsAre Analysts Bearish Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Last Week?Wall Street Hints and Newsall 21 news articles »
05/22/16 04:58 PMNext Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Share Trading News - Next Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Share Trading News08/10/2015 – Lexicon Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 14 price target on the stock. 05/01/2015 – Lexicon Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Zacks.and more »
05/22/16 10:04 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) One-Year Price Target Estimate At $20.10 - RealistInvestor.com - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) One-Year Price Target Estimate At $20.10RealistInvestor.comThe 52-week price target of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is set at $20.10 after First Call completed its market based survey. It has estimated EPS of $-0.51 for approaching quarter and $-1.54 for ongoing year. The EPS estimate for next ...and more »
05/21/16 05:09 PMLexicon Pharmaceuticals (NASDAQ:LXRX) To Report June 2016 Results - Street Register - Lexicon Pharmaceuticals (NASDAQ:LXRX) To Report June 2016 ResultsStreet RegisterLexicon Pharmaceuticals, Inc. (LXRX) retreated -2.07% to reach at the floor price of $12.29 as the company is set to share its next quarterly earnings on July 26, 2016. LXRX stock trades between $12.13 and $12.72 before the earnings release. Let's take ...and more »
05/20/16 05:28 PMNotable Buzzers: Cynosure, Inc. (NASDAQ:CYNO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Street Updates - Notable Buzzers: Cynosure, Inc. (NASDAQ:CYNO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Street UpdatesLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) after beginning at $12.52, closed at $12.29 by cutting down -2.07% in recent trading session. Most recent session's volume of 532.25 thousand shares lower than its average volume of 721.39 thousand shares.Lexicon Pharmaceuticals (NASDAQ:LXRX) To Report June 2016 ResultsStreet Registerall 2 news articles »
05/20/16 09:05 AMLexicon Pharmaceuticals (NASDAQ:LXRX) To Report June 2016 Results - Lexicon Pharmaceuticals, Inc. (LXRX) retreated -2.07% to reach at the floor price of $12.29 as the company is set to share its next quarterly earnings on July 26, 2016. LXRX stock trades between $12.13 and $12.72 before the earnings release. Let’s take a ...
05/18/16 09:39 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Hovering Around $12.69 - Investor Newswire - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Hovering Around $12.69Investor NewswireOn performing technical analysis of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock, it is noted that the stock is $-0.66 points away -4.98% from its fifty-day MA of $13.19. It is $0.61 or +5.12% away $11.92, the 200-day MA (Moving Average) of stock ...Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Latest Broker ViewsRisers & Fallersall 2 news articles »
05/17/16 05:22 PMShare Recap and Earnings Focus on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Lexicon Pharmaceuticals, ...and more »
05/14/16 05:11 PMHealthcare Stock to target: BioDelivery Sciences International, Inc. (NASDAQ:BDSI) , Lexicon Pharmaceuticals, Inc ... - Is stories - Healthcare Stock to target: BioDelivery Sciences International, Inc. (NASDAQ:BDSI) , Lexicon Pharmaceuticals, Inc ...Is storiesIn most recently trading session on 5/13/2016, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) climbed +3.73% while traded on 332.47 thousand shares versus it's an average volume of 726.37 thousand shares. The company recorded the last trade with the ...and more »
05/13/16 05:47 PMLXRX Crosses Below Key Moving Average Level - In trading on Thursday, shares of Lexicon Pharmaceuticals, Inc. (Symbol: LXRX) crossed below their 200 day moving average of $11.75, changing hands as low as $11.52 per share. Lexicon Pharmaceuticals, Inc. shares are currently trading off about 4.2% on the ...
05/12/16 12:04 PMLEXICON PHARMACEUTICALS, INC. Financials -
05/11/16 04:01 AMConsensus Rating Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - B.O.D.Y Confidential - Consensus Rating Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2.5 on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company's sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LXRX
  • CUSIP: 52887210
Key Metrics:
  • Previous Close: $13.14
  • 50 Day Moving Average: $13.49
  • 200 Day Moving Average: $12.14
  • P/E Ratio: N/A
  • P/E Growth: -0.17
  • Market Cap: $1.36B
  • Current Quarter EPS Consensus Estimate: $-1.54 EPS
Additional Links:
Lexicon Pharmaceuticals (NASDAQ:LXRX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha